CN1219430A - Weight gaining preparation and extraction method of medicinal components thereof - Google Patents
Weight gaining preparation and extraction method of medicinal components thereof Download PDFInfo
- Publication number
- CN1219430A CN1219430A CN 97114319 CN97114319A CN1219430A CN 1219430 A CN1219430 A CN 1219430A CN 97114319 CN97114319 CN 97114319 CN 97114319 A CN97114319 A CN 97114319A CN 1219430 A CN1219430 A CN 1219430A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- accounts
- preparation
- fattening
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 68
- 238000000605 extraction Methods 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims description 45
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 24
- 241000756943 Codonopsis Species 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 39
- 239000002994 raw material Substances 0.000 abstract description 10
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000007812 deficiency Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 240000007594 Oryza sativa Species 0.000 abstract description 4
- 235000007164 Oryza sativa Nutrition 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 235000009566 rice Nutrition 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 abstract description 3
- 238000011047 acute toxicity test Methods 0.000 abstract description 3
- 231100001252 long-term toxicity Toxicity 0.000 abstract description 3
- 244000197580 Poria cocos Species 0.000 abstract description 2
- 235000008599 Poria cocos Nutrition 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 208000026500 emaciation Diseases 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- 241001465754 Metazoa Species 0.000 description 31
- 230000037396 body weight Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 230000008901 benefit Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 229920002527 Glycogen Polymers 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 229940096919 glycogen Drugs 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000004051 gastric juice Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002440 hepatic effect Effects 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 102000013142 Amylases Human genes 0.000 description 5
- 108010065511 Amylases Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000019418 amylase Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 208000007882 Gastritis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010025476 Malabsorption Diseases 0.000 description 4
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 4
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 206010026820 marasmus Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029158 Nephroptosis Diseases 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010041611 Spine malformation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 241001247821 Ziziphus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a weight-gaining preparation and an extraction method of medicinal components thereof. The weight increasing preparation of the invention is prepared by taking several components of spina date seed, codonopsis pilosula, bighead atractylodes rhizome, dried orange peel, rice sprout, poria cocos and coix seed as raw materials. The weight-gaining preparation is developed according to the theory of traditional Chinese medicine, has obvious and definite curative effect on emaciation caused by deficiency of spleen and qi and blood, and has safety and no obvious adverse reaction when being taken as shown by the results of acute toxicity test research and long-term toxicity test research.
Description
The present invention relates to the extracting method of a kind of fattening preparation and active ingredient thereof.
Now " fat-reducing " in vogue, the fat-reducing medicine emerges in an endless stream.Yet very important, the home and abroad still has many because of suffering from the people that " becoming thin " seeks medical advice and medicine everywhere.Marasmus also can cause numerous disease, as visceroptosis (wherein, nephroptosis easily causes repeatedly the difficult urinary tract infection that heals again), spine malformation, immunity degradation, female uterine prolapse, irregular menstruation, infertility etc.As seen, treatment is become thin and be can not be ignored, and treatment is become thin significant to improving China's population quality effectively.At present, along with the development of society, marasmus is not to be to eat cream fat very little, and famine is not wrapped up in due to the abdomen, but weakens relevant with the transporting and transforming function of the spleen and stomach absorption function.The medicine of aspect that thin rich body " is controlled " in present home and abroad is but very deficient.
The object of the present invention is to provide a kind of preparation for the treatment of the marasmus due to the insufficiency of the spleen insufficiency of vital energy and blood.Another object of the present invention is to provide the extracting method of the active ingredient of this fattening preparation.
Fattening preparation of the present invention is made as raw material by several compositions of Semen Ziziphi Spinosae, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Fructus Oryzae Germinatus, Poria and Semen Coicis, wherein Semen Ziziphi Spinosae accounts for 17.8～37.8 weight portions, Radix Codonopsis accounts for 12.2～32.2 weight portions, the Rhizoma Atractylodis Macrocephalae accounts for 3.4～13.4 weight portions, Pericarpium Citri Reticulatae accounts for 3.4～13.4 weight portions, Fructus Oryzae Germinatus accounts for 6.1～16.1 weight portions, and Poria accounts for 6.1～16.1 weight portions, and Semen Coicis accounts for 6.1～16.1 weight portions.This fattening preparation can be made various dosage forms such as oral liquid, capsule, soft capsule, tablet, pill, honey pill agent as required.
According to technique scheme, preferably get the various raw material compositions of following ratio and make.Wherein Semen Ziziphi Spinosae accounts for 27.8 weight portions, and Radix Codonopsis accounts for 22.2 weight portions, and the Rhizoma Atractylodis Macrocephalae accounts for 8.35 weight portions, and Pericarpium Citri Reticulatae accounts for 8.35 weight portions, and Fructus Oryzae Germinatus accounts for 11.1 weight portions, Poria 11.1 weight portions, and Semen Coicis accounts for 11.1 weight portions.
The extracting method of the active ingredient of above-mentioned fattening preparation is as follows: with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria pulverize medicated powder; Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water are decocted, the gained medicinal liquid through concentrate concentrated solution; Concentrated solution is mixed with pulverizing gained medicated powder.
According to technique scheme, with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, when Poria is pulverized, if pulverize separately, then the flour extraction of each medical material differs bigger, be more or less the same and pulverize separately, and it is easy and simple to handle to mix pulverizing, so preferably select the mixing breaking method for use with mixing the average flour extraction of pulverizing.
The quality standard of preparation raw material (medical material):
1. Semen Ziziphi Spinosae
This product is Rhamnaceae plant Ziziphi Spinosae Ziziphus iuiuba Mill.Var.Spinosa (Bunge) Hu ex H.F.Chou dry mature seed.
2. Radix Codonopsis
This product is the dry root of campanulaceae plant Radix Codonopsis Codonopsis Silosula (Franch.) Nannf..
3. the Rhizoma Atractylodis Macrocephalae
This product is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Aractylodes macrocephala Koidz..
4. Poria
This product is the dry sclerotia of Polyporaceae fungus Poria Poria cocos (Schw.) Wolf.
5. Pericarpium Citri Reticulatae
This product is the dry mature skin of rutaceae orange Citrus reticulata Blanco and variety thereof.
6. Semen Coicis
This product is the dry mature kernal of grass Semen Coicis Coix lacryma-iobi L.var.ma-yuen (Roman) Stapf.
7. Fructus Oryzae Germinatus
This product is that the mature fruit of grass rice Qryza Sativa L. gets through germination treatment.
Above medical material all need meet the Chinese Pharmacopoeia specified standard.
Fattening preparation of the present invention is to develop according to theory of Chinese medical science, and evident in efficacy, definite to the marasmus due to the insufficiency of the spleen insufficiency of vital energy and blood, acute toxicity test research and long term toxicity test result of study all show, take said preparation safety, no obvious adverse reaction.
The invention will be further described below in conjunction with embodiment.
Embodiment 1:
The present embodiment fattening preparation is got the various raw material compositions of following ratio and is made pill.Semen Ziziphi Spinosae 27.8 weight portions wherein, Radix Codonopsis 22.2 weight portions, the Rhizoma Atractylodis Macrocephalae 8.35 weight portions, Pericarpium Citri Reticulatae 8.35 weight portions, Fructus Oryzae Germinatus 11.1 weight portions, Poria 11.1 weight portions, Semen Coicis 11.1 weight portions.
Extract its active ingredient as follows: the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria pulverize medicated powder; Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water are decocted, the gained medicinal liquid through concentrate concentrated solution; Concentrated solution is mixed with pulverizing gained medicated powder.
The toxicity test result:
1. acute toxicity test research
With 30% fattening preparation extract powder 0.8%ml/20g body weight 1 time (360g crude drug in whole/kg/ time), two groups of first, second are (with 40 of healthy one-level animal Kunming kind white mice in 24 hours, male and female half and half, branch first, second group at random) irritates stomach respectively 2 times, 3 times, raise routinely after irritating stomach, observed seven days, two groups of mices do not have death and other abnormal symptoms.The maximum tolerated dose of gastric infusion is 108g crude drug in whole/kg/ day, calculates with maximum tolerance multiple formula, and this dosage is 300 times of adult's (50kg body weight) clinical consumption.And after raising 7 days, mice is taken off vertebra and put to death all no abnormal discovery of the vitals of perusal mice (heart, liver, spleen, lung, kidney etc.).
2. long term toxicity test research:
Weight gaining benefit health ball successive administration 90 days is to rat hemogram liver function, serum glucose.The influence of 10 projects such as tissue morphology of cholesterol, body weight, organ index, vitals.Experimental result shows: high, medium and low three dosage of weight gaining benefit health ball are continuously to rat oral gavage administration 90 days, to liver, the renal function of animal, and hemogram, serum cholesterol, glucose and growth promoter all do not have the overt toxicity detrimental effect; Under optical microscope the rat heart, liver, spleen, lung, kidney, adrenal gland, stomach have been carried out the tectology inspection, the result does not all find tangible pathomorphology infringement.
Test of pesticide effectiveness result:
1. promote the small intestinal absorption function
(1) to the influence of rat food ration
Choose 50 of healthy SD kind rats, body weight 90 ± 10g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 40 days, the normal saline group gives the isometric(al) normal saline, and writes down each treated animal food ration every day, continuous record 40 days, with per 10 days be one-period, calculate in 4 cycles each treated animal average magnitude of ingesting every day, carry out statistical procedures, the results are shown in Table 1.
Table 1 result shows, weight gaining benefit health ball successive administration 40 days, and large, medium and small dosage group (7.2g/kg, 3.6g/kg, 1.8g/kg) can increase animal ingestion amount (p＜0.05) in the different cycles, illustrates that it has obvious facilitation to appetite.
Table 1
| Average food ration every day (g/ day) | ||||||
| ????1～10d | ????11～20d | ????21～30d | ????31～40d | |||
| Normal saline fattening preparation fattening preparation fattening preparation XIANGSHA LIUJU WAN | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 7.2 3.6 1.8 3.6 | ?169.98±65?48 ?193.80±61.65 ?165.42±27.73 ?171.58±54.64 ?172.28±31.25 | ??175.06±27.86 ??224?34±50.65 *??198?98±30.09 ??197.64±35.41 ??203.76±43.39 | 194.48±21?62 218.78±21.75 *231.28±23.95 **234.53±20.20 ***201.84±24.53 | 194.42±21.01 209.25±23?55 223.29±28.47 *239.43±27.19 ***220.11±24.63 * |
(2) influence that fatty tissue is formed.
Choose 50 of healthy SD kind rats, body weight 80～100g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 48 days, the normal saline group gives the isometric(al) normal saline, and administration was put to death animal after 48 days, took by weighing around groin, the kidney and the whole fat weights of intraperitoneal, and calculated corresponding coefficient (the g/100g body gets), the results are shown in Table 2.
Table 2 is the result show, to fat coefficient and fat weight, and the weight gaining benefit health heavy dose of group of ball (7.2g/kg) trend that improves, but not statistically significant (p＞0.05).
Table 2
Annotate: compare p＞0.05 with the normal saline group
| Group | Animal (only) | Dosage (g/kg) | Fat coefficient (g/100g body weight) | Fat weight (g) |
| Normal saline XIANGSHA LIUJU WAN fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 3.6 7.2 3.6 1.8 | ????2.266±0.966 ????2.871±1.400 ????2.469±1.009 ????2.390±0.890 ????2.005±0.754 | ?5.145±2.520 ?5.782±3.000 ?5.547±2.396 ?5.071±2.141 ?4.946±1.386 |
2. facilitating digestion effect (1) is to the influence of gastric acid, pepsin acid activity
Choose 50 of healthy SD kind rats, body weight 180～200g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 12 days, the normal saline group gives the isometric(al) normal saline, after the last administration, with animal fasting 24 hours, after 24 hours with 3% pentobarbital sodium normal saline solution intraperitoneal anesthesia rat, the ligation pylorus was put to death rat after 6 hours, collected gastric juice determining gastric juice amount, centrifugal gastric juice removes slag simultaneously, press titration measuring gastric juice free acid and total acidity, measure pepsin activity, the results are shown in Table 3 by wheat Te Shi method.
Table 3 is the result show, the large, medium and small dosage of fattening preparation is fed and all can obviously be improved pepsic activity (p＜0.001), acts on stronger than positive drug; Dosage group big or middle can improve gastric juice free acidity (p＜0.05).
Table 3
| Group | Animal (only) | Dosage (g/kg) | The gastric juice amount | Gastric juice free acid (unit) | Gastric juice total acid (unit) | Pepsin (unit/ml) |
| Normal saline XIANGSHA LIUJU WAN fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 36 72 36 18 | ?955±4.35 ?700±251 ?10.31±110 ?6.38±296 ?883±445 | 41.85±11.69 29.43±7.05 *55.75±11.78 *61.29±19.45 *42.57±15.62 | ?68.47±10.96 ?69.43±12.93 ?81.63±17.22 ?72.25±24.52 ?80.86±19.96 | 40.57±4.23 46.86±11.05 61.00±8.49 **△△60.62±11.70 ***△54.86±7.92 *** |
(2) to the active influence of serum amylase
Choose 50 of healthy SD kind rats, body weight 90 ± 10g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 48 days, the normal saline group gives the isometric(al) normal saline, and administration is after 48 days, and the sacrificed by decapitation animal is got blood and separation of serum, presses iodine colorimetry and measures serum amyloid enzymatic activity, table 4 as a result.
Table 4 is the result show, weight gaining benefit health ball successive administration 48 days, and 3.6g/kg, 1.8g/kg dosage group can obviously improve rat blood serum amylase activity (p＜0.01).
Table 4
Annotate: 1) the normal saline group relatively
*P＜0.01,
* *P＜0.001
| Group | Animal (only) | Dosage (g/kg) | Amylase unit/100ml serum |
| Normal saline XIANGSHA LIUJU WAN fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 3.6 7.2 3.6 1.8 | ?1706.14±123.52 ?2390.59±327.74 ***?1805.06±316.60 ?2257.86±537.24 **?2257.54±239.07 *** |
2) in 37 ℃ of 30min, be called 1 amylase unit in the 100ml serum during amylase complete hydrolysis starch 10ml.
3. to lipometabolic influence
Choose 50 of healthy SD kind rats, body weight 120 ± 20g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 30 days, the normal saline group gives the isometric(al) normal saline, and administration is after 30 days, and the sacrificed by decapitation animal is got blood and separation of serum, measures serum levels of triglyceride and cholesterol level, table 5 as a result.
Table 5 is the result show, weight gaining benefit health ball successive administration 30 days has certain reduction effect to serum cholesterol content, but not statistically significant (p＞0.05); Dosage group big or middle (7.2g/kg, 3.6g/kg) can obviously reduce serum levels of triglyceride level (p＜0.05), and is being equal under the dosage, and its effect that reduces serum triglyceride level is better than XIANGSHA LIUJU WAN group (p＜0.01).
Table 5
Annotate: compare with the normal saline group
*P＜0.05; Compare with the XIANGSHALIUJUNZI group
△ △ △P＜0.001
| Group | Animal (only) | Dosage (g/kg) | Order oil three esters (mg/dl) | Cholesterol (mg/dl) |
| Normal saline XIANGSHA LIUJU WAN weight gaining benefit health ball weight gaining benefit health ball weight gaining benefit health ball | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 3.6 7.2 3.6 1.8 | ?122.09±32.22 ?122.60±7.19 ?97.93±17.19 *?94.15±16.00 *△△△?104.34±8.31 | ?40.67±5.91 ?44.10±6.06 ?35.80±7.52 ?36.20±6.09 ?36.20±8.23 |
4. to the influence of muscle glycogen, hepatic glycogen and serum blood sugar level
Choose 50 of healthy SD kind rats, body weight 120 ± 20g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 30 days, the normal saline group gives the isometric(al) normal saline, after the administration 30 days, the sacrificed by decapitation animal, get blood and separation of serum and measure serum glucose level, take by weighing liver and each 0.5g of quadriceps femoris meat simultaneously, boil hydrolysis with 30%KOH solution after, press anthrone method and measure liver glycogen and muscle glycogen content, the results are shown in Table 6.
Table 6 is the result show, fattening preparation successive administration 30 days, and each dosage group has certain reduction effect (p＜0.01) to the rat blood serum blood sugar level; Hepatic glycogen and muscle glycogen content all there are the utmost point effect of significantly improving (p＜0.001), illustrate that it can promote glycogen synthetic.
Table 6
Annotate: the normal saline group relatively
*P＜0.01
* *P＜0.001
| Group | Animal (only) | Dosage (g/kg) | Muscle glycogen (g/100g muscle) | Hepatic glycogen (g/100g hepatic tissue) | Blood glucose (mg/dl) |
| Normal saline XIANGSHA LIUJU WAN fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 3672 3.6 1.8 | 0.202±0.030 0.268±0.036 ***0.301±0.046 ***0.299±0.044 ***0.269±0.041 *** | 0.331±0.047 0.419±0.277 **0.614±0.277 **0.621±0.102 ***0.566±0.146 *** | ?92.22±11.99 ?88.20±16.37 ?73.00±12.37 ?55.50±17.56 ***?65.60±42.74 |
5. to the influence of protein, nucleic acid metabolism
Choose 50 of healthy SD kind rats, body weight 120 ± 20g, male and female half and half are divided into five groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g, 1.8g/kg) and XIANGSHA LIUJU WAN group (3.6g/kg).The continuous gastric infusion of every treated animal 30 days, the normal saline group gives the isometric(al) normal saline, and administration is after 30 days, and the sacrificed by decapitation animal is got blood and separation of serum, presses biuret method and bromocresol green method and measures total serum protein and albumin content; Take by weighing a certain amount of liver organization simultaneously, press DNA, RNA and nucleic acid total content in the determined by ultraviolet spectrophotometry liver, the results are shown in Table 7, table 8.
Table 7 result shows that fattening preparation successive administration 30 days is significantly increased effect (p＜0.05) to the rat blood serum total protein content, with middle dosage group (3.6g/Kg) effect obvious (p＜0.001); To serum albumin levels influence not obvious (p＜0.05).
Table 8 result shows, fattening preparation successive administration 30 days influences not significantly (p＞0.05) to rna content in the hepatic tissue and nucleic acid total amount; 7.2g/kg the dosage group can improve dna content in the hepatic tissue (p＜0.1); To each dosage group of RNA/DNA ratio trend that all improves, illustrate that weight gaining benefit health ball has the effect that promotes animal growth.
Table 7.
Annotate: compare with normal saline
*P＜0.05
*P＜0.01
* *P＜0.001
| Group | Animal (only) | Dosage (g/kg) | Total protein (g/L) | Albumin (g/L) |
| Normal saline XIANGSHA LIUJU WAN fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 3.6 7.2 3.6 1.8 | 80.80±4.23 85.60±4.09 *86.89±5.88 *91.30±3.27 ***86.00±3.89 * | ?40.11±3.78 ?43.00±2.94 ?40.80±3.77 ?40.45±3.01 ?41.20±1.81 |
Table 8
* ￠: compare with normal saline
*P＜0.01
| Group | Animal (only) | Dosage (g/kg) | DNA (mg/g liver) | RNA (mg/g liver) | ????RNA/DNA | Nucleic acid total amount (mg/g liver) |
| Normal saline XIANGSHA LIUJU WAN fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 ????10 | Isometric(al) 3.6 7.2 7.2 1.8 | ????1.020±0.11 ????1.136±0.39 ????1.344±0.33 **????1.168±0.26 ????1.062±0.21 | ????10.058±0.96 ????10.682±1.82 ????9.100±1.12 ????10.736±1.54 ????10.348±1.24 | ????8.990±0.79 ????10.350±4.45 ????7.280±2.39 ????9.210±2.77 ????9.360±2.01 | ????11.358±0.94 ????11.818±1.36 ????10.444±1.15 ????11.928±1.52 ????11.464±1.32 |
Sedation-with the synergism of barbiturate
Choose 40 of healthy SD kind rats, body weight 18～22g, male and female half and half are divided into four groups by the body weight stratified random, are respectively normal saline group, large, medium and small three the dosage groups of fattening preparation (7.2g/kg, 3.6g/kg, 1.8g/kg).The continuous gastric infusion of medicine group 6 days, the normal saline group gives the isometric(al) normal saline, 30min after each treated animal last administration, every mouse peritoneal is injected 0.3% pentobarbital sodium solution 30mg/kg, observe each treated animal time for falling asleep (mice righting reflex loss 1min above as sleeping index), sleeping number and the length of one's sleep (from the sleeping time of recovering to righting reflex be the length of one's sleep of animal), the results are shown in Table 9.
Table 9 is the result show, fattening preparation can prolong the length of one's sleep of injection pentobarbital sodium animal, with heavy dose group (7.2g/kg) effect obvious (p＜0.01), shows that fattening preparation and barbiturate have synergism, illustrates that it has sedation.
Table 9
Annotate: compare with the normal saline group
*P＜0.05
*P＜0.01
| Group | Animal (only) | Dosage (g/kg) | Sleeping number | Time for falling asleep (min) | The length of one's sleep (min) |
| Normal saline fattening preparation fattening preparation fattening preparation | ????10 ????10 ????10 ????10 | Isometric(al) 7.2 3.6 1.8 | ????8/10 ????10/10 ????10/10 ????10/10 | ?4.33±2.08 ?4.03±1.26 ?4.50±1.25 ?4.56±2.17 | ?16.50±4.86 ?32.17±10.96 **?23.10±10.87 ?21.33±4.20 * |
In October, 1996 to 1996, year December was the clinical verification responsible department that fattening preparation is treated the spleen deficiency of becoming thin by Hospital Affiliated To Chengdu Traditional Chinese Medicine Univ, and the curative effect and the safety of this medicine are observed and evaluated.Adopt counter point at random, control drug is selected XIANGSHA LIUJU WAN for use, and oral fattening preparation is organized in treatment, each 3g, every day 3 times, preceding 1 hour clothes of eliminating cold for resuscitation cooked rice reboiled in water or soup, the oral XIANGSHA LIUJU WAN of matched group, each 6g, every day 3 times, preceding 1 hour clothes of eliminating cold for resuscitation cooked rice reboiled in water or soup.Case 183 examples are observed in clinical verification altogether, and wherein 121 examples are organized in treatment, matched group 62 examples.Clinical results: total obvious effective rate that fattening preparation is treated the spleen deficiency of becoming thin is 75.21%, and effective percentage is 86.78%, and its obvious effective rate and effective percentage all obviously are better than matched group; To the become thin obvious effective rate of chronic superficial gastritis of spleen deficiency of genus is 75.41%, and effective percentage is 85.25%; The obvious effective rate of malabsorption syndrome is 75.00%, and effective percentage is 88.33%.Clinical results also shows, fattening preparation has obvious curative effects to the become thin clinical symptoms of spleen deficiency of improvement, especially to improving appetite go down, the curative effect of spiritlessness and sparing of words is better than matched group.Do not find in the clinical verification that this medicine has obvious adverse reaction, takes safety.Now Clinical results is summarized as follows:
1. case is originated
According to the requirement of fattening preparation clinical verification plan, selected respectively to be in hospital and the out-patient.In 183 routine chronic superficial gastritiss and malabsorption syndrome patient, inpatient 75 examples, out-patient's 108 examples, inpatient example number accounts for 40.98% of total routine number.
2. sex
Male's 97 examples in the 183 routine cases, women's 86 examples, man: woman=1.13: 1.Treatment group and matched group sex composition are learned by statistics and are handled p＞0.05, and difference does not have significance.
3. age
Two groups of patient ages distribute and the mean age comparison, and learn by statistics and handle, p＞0.05, difference does not have significance.
4. the course of disease
Two groups of patient's courses of disease are relatively learned by statistics and are handled, p＞0.05, and difference does not have significance.5. (1) two group of total effects of therapeutic effect is as shown in table 10.
Table 10. liang group total effects relatively
| Group | The example number | Curative effect | Obvious effective rate (%) | Total effective rate (%) | |||
| Recovery from illness | Produce effects | Effectively | Invalid | ||||
| Treatment group matched group | 121 ％ 62 ％ | ?41 ?33.88 ?11 ?17.74 | ?50 ?41.32 ?18 ?29.03 | ?14 ?11.57 ?12 ?19.35 | ?16 ?13.22 ?21 ?33.87 | ?75.21 ?46.77 | ?86.78 ?66.13 |
Treatment back treatment group and matched group curative effect are analyzed through RIDIT, and R controls=0.4453, and R is right=and 0.6068, u=3.58, p＜0.01, difference has utmost point significance; Two groups of obvious effective rates compare, through X
2Check, X
2=13.45, difference has utmost point significance, and two groups of effective percentage compare, through X
2Check, X
2=9.59, difference has utmost point significance, illustrates that treatment group curative effect is better than matched group.
(2) different sick kinds are as shown in table 11 with the relation of curative effect.
The relation of sick kind of table 11. and curative effect
| The sick kind | The example number | Treatment group (121 example) | Obvious effective rate (%) | Total effective rate (%) | |||
| Clinical recovery | Produce effects | Effectively | Invalid | ||||
| Chronic superficial gastritis malabsorption syndrome | 61 ％ 60 ％ | ????20 ?32.79 ????17 ????28.33 | ????26 ?42.62 ????28 ?46.67 | ????6 ?9.84 ????8 ?13.33 | ????9 ?14.75 ????7 ?11.67 | ?75.41 ?75.00 | ?85.25 ?88.33 |
Each sickly plants curative effect relatively treatment back, analyzes through RIDIT, and R is slow=and 0.4930, R inhales=0.5071, u=0.27, p＞0.05, difference does not have significance, illustrates that the treatment group is similar to chronic superficial gastritis, malabsorption syndrome curative effect.
(3) two groups of treatment back body weight integration curative effects relatively
Table 16. treatment back body weight integration curative effect relatively
| Group | The example number | The body weight integration | ||
| Before the treatment | After the treatment | Difference | ||
| Treatment group matched group | ????121 ????62 | ????3.83±1.62 ????3.70±1.56 | ????2.34±1.35 ????3.45±1.50 | ????1.49±1.14 ????0.24±0.98 |
The difference of body weight integration difference own control is relatively checked through t behind treatment group and the matched group patient treatment, t difference=14.38,1.92, and treatment group p value＜0.01 illustrates that the treatment group has the effect of rising body weight.
The relation of (4) treatment group patient age and curative effect
The relation of table 17. treatment group age and curative effect
There is not obvious relation by table 17 explanation treatment group age and curative effect.The relation of (5) treatment group patient's course of disease and curative effect
| The example number | Age (X ± SD) | |
| Recovery from illness and produce effects case effectively reach invalid case | ????91 ????30 | ????37.32±10.24 ????37.53±10.55 |
The relation of the table 18. treatment group course of disease and curative effect
| The example number | The course of disease (X ± SD) | |
| Recovery from illness and produce effects case effectively reach invalid case | ????91 ????30 | ????3.37±1.96 ????3.66±2.07 |
By table 18 explanation, the treatment group course of disease and curative effect do not have obvious relation.
Embodiment 2:
The present embodiment fattening preparation is got the various raw material compositions of following ratio and is made oral liquid.Semen Ziziphi Spinosae 22.8 weight portions wherein, Radix Codonopsis 20.2 weight portions, the Rhizoma Atractylodis Macrocephalae 9.35 weight portions, Pericarpium Citri Reticulatae 9.35 weight portions, Fructus Oryzae Germinatus 12.1 weight portions, Poria 13.1 weight portions, Semen Coicis 13.1 weight portions.
Mentioned component is extracted by the following method: with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria mix pulverize medicated powder; With Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water decoct the gained medicinal liquid through concentrate concentrated solution; The medicated powder of concentrated solution being pulverized the back gained mixes.
Embodiment 3:
The present embodiment fattening preparation is got the various raw material compositions of following ratio and is made capsule.Semen Ziziphi Spinosae 25.8 weight portions wherein, Radix Codonopsis 20.2 weight portions, the Rhizoma Atractylodis Macrocephalae 8.35 weight portions, Pericarpium Citri Reticulatae 8.35 weight portions, Fructus Oryzae Germinatus 13.1 weight portions, Poria 12.1 weight portions, Semen Coicis 12.1 weight portions.
Mentioned component is extracted its active ingredient by the following method: with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria mix pulverize medicated powder; With Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water decoct the gained medicinal liquid through concentrate concentrated solution; The medicated powder of concentrated solution being pulverized the back gained mixes.
Embodiment 4:
The present embodiment fattening preparation is got the various raw material compositions of following ratio and is made soft capsule.Semen Ziziphi Spinosae 30.8 weight portions wherein, Radix Codonopsis 20.2 weight portions, the Rhizoma Atractylodis Macrocephalae 8.35 weight portions, Pericarpium Citri Reticulatae 8.35 weight portions, Fructus Oryzae Germinatus 10.1 weight portions, Poria 11.1 weight portions, Semen Coicis 11.1 weight portions.
Mentioned component is extracted its active ingredient by the following method: with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria mix pulverize medicated powder; With Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water decoct the gained medicinal liquid through concentrate concentrated solution; The medicated powder of concentrated solution being pulverized the back gained mixes.
Embodiment 5:
The present embodiment fattening preparation is got the various raw material compositions of following ratio and is made tablet.Semen Ziziphi Spinosae 27.8 weight portions wherein, Radix Codonopsis 19.2 weight portions, the Rhizoma Atractylodis Macrocephalae 9.35 weight portions, Pericarpium Citri Reticulatae 10.35 weight portions, Fructus Oryzae Germinatus 10.1 weight portions, Poria 10.1 weight portions, Semen Coicis 13.1 weight portions.
Mentioned component is extracted its active ingredient by the following method: with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria mix pulverize medicated powder; With Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water decoct the gained medicinal liquid through concentrate concentrated solution; The medicated powder of concentrated solution being pulverized the back gained mixes.
Embodiment 6:
The present embodiment fattening preparation is got the various raw material compositions of following ratio and is made honey pill agent.Semen Ziziphi Spinosae 24.8 weight portions wherein, Radix Codonopsis 19.2 weight portions, the Rhizoma Atractylodis Macrocephalae 10.35 weight portions, Pericarpium Citri Reticulatae 9.35 weight portions, Fructus Oryzae Germinatus 12.1 weight portions, Poria 12.1 weight portions, Semen Coicis 12.1 weight portions.
Mentioned component is extracted its active ingredient by the following method: with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria mix pulverize medicated powder; With Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water decoct the gained medicinal liquid through concentrate concentrated solution; The medicated powder of concentrated solution being pulverized the back gained mixes.
Clinical experiment shows that the fattening preparation of embodiment 2-embodiment 6 takes safety, no obvious adverse reaction, and therapeutic effect is also similar with the pill of embodiment 1.
Claims (4)
1. fattening preparation, it is characterized in that it is by Semen Ziziphi Spinosae, Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Fructus Oryzae Germinatus, the oral formulations that several compositions of Poria and Semen Coicis are made as medicine material, dosage form can be an oral liquid, tablet, capsule, soft capsule, pill, honey pill agent etc., wherein the ratio of medicine material is that Semen Ziziphi Spinosae accounts for 17.8～37.8 weight portions, Radix Codonopsis accounts for 12.2～32.2 weight portions, the Rhizoma Atractylodis Macrocephalae accounts for 3.4～13.4 weight portions, Pericarpium Citri Reticulatae accounts for 3.4～13.4 weight portions, Fructus Oryzae Germinatus accounts for 6.1～16.1 weight portions, Poria accounts for 6.1～16.1 weight portions, and Semen Coicis accounts for 6.1～16.1 weight portions.
2. fattening preparation according to claim 1, it is characterized in that wherein the ratio of medicine material accounts for 27.8 weight portions with Semen Ziziphi Spinosae, Radix Codonopsis accounts for 22.2 weight portions, the Rhizoma Atractylodis Macrocephalae accounts for 8.35 weight portions, Pericarpium Citri Reticulatae accounts for 8.35 weight portions, Fructus Oryzae Germinatus accounts for 11.1 weight portions, and Poria accounts for 11.1 weight portions, and it is good that Semen Coicis accounts for 11.1 weight portions.
3. the extracting method of the active ingredient of a fattening preparation as claimed in claim 1, it is characterized in that with the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria pulverize medicated powder; With Semen Ziziphi Spinosae, Radix Codonopsis, Fructus Oryzae Germinatus water decoct the gained medicinal liquid through concentrate concentrated solution; Concentrated solution is mixed with the medicated powder of pulverizing the back gained.
4. extracting method according to claim 3 is characterized in that the Rhizoma Atractylodis Macrocephalae, Pericarpium Citri Reticulatae, Semen Coicis, Poria mixing are pulverized.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97114319 CN1219430A (en) | 1997-12-12 | 1997-12-12 | Weight gaining preparation and extraction method of medicinal components thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97114319 CN1219430A (en) | 1997-12-12 | 1997-12-12 | Weight gaining preparation and extraction method of medicinal components thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1219430A true CN1219430A (en) | 1999-06-16 |
Family
ID=5172879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97114319 Pending CN1219430A (en) | 1997-12-12 | 1997-12-12 | Weight gaining preparation and extraction method of medicinal components thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1219430A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119775A (en) * | 2011-01-21 | 2011-07-13 | 无限极（中国）有限公司 | Dried orange peel extract and preparation method and application thereof |
-
1997
- 1997-12-12 CN CN 97114319 patent/CN1219430A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119775A (en) * | 2011-01-21 | 2011-07-13 | 无限极（中国）有限公司 | Dried orange peel extract and preparation method and application thereof |
| CN102119775B (en) * | 2011-01-21 | 2015-04-29 | 无限极（中国）有限公司 | Dried orange peel extract and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102198262B (en) | Chinese medicine preparation for treating infant rotavirus enteritis and preparation method thereof | |
| CN103566346B (en) | A kind of medicine and preparation method for the treatment of person in middle and old age's abdominal distention | |
| CN103431276A (en) | Mixed-grain total-nutrition formulation food for patients with inflammatory bowel diseases | |
| CN106729123A (en) | A kind of composition of three high drop and preparation method thereof | |
| CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN101468173B (en) | Chinese medicinal composition for treating children's indigestion and preparation method thereof | |
| CN1958035A (en) | Composition of medication in use for reducing blood sugar, blood fat, and treating diabetes | |
| CN1772257A (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN103798596B (en) | Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases | |
| CN102552743A (en) | Medicinal composition for treating diabetes and preparation method thereof | |
| CN1299732C (en) | Chinese medicine preparation for treating fatty liver | |
| CN1219430A (en) | Weight gaining preparation and extraction method of medicinal components thereof | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN116549595B (en) | Pharmaceutical composition for treating functional dyspepsia of children, preparation and application thereof | |
| CN115607634B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and gout and application thereof | |
| CN116763880B (en) | Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method | |
| CN101147787A (en) | Red glossy ganoderma Chinese medicinal herb composition | |
| CN1380080A (en) | Medicine for curing fatty liver | |
| CN105770205A (en) | Pharmaceutical composition containing felodipine and capable of treating hypertension and preparation method thereof | |
| CN112691179A (en) | Traditional Chinese medicine composition for losing weight and preparation method thereof | |
| CN1196493C (en) | Medicines for treating sterility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |